Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241430 | 0.94 | KAT2B (0.48) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL7371227 | 0.81 | RAB9A (0.61) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL4245982 | 0.81 | KAT2B (0.52) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL762635 | 0.79 | KAT2B (0.60) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL20337732 | 0.79 | KAT2B (0.49) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL29525978 | 0.78 | MAPT (0.53) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL6182039 | 0.78 | MAPT (0.53) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL20571599 | 0.78 | LMNA (0.63) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL8246358 | 0.78 | KAT2B (0.58) | KAT2BMAPTPKMLMNAVCAM1 | |
| SCHEMBL29737974 | 0.78 | LMNA (0.63) | KAT2BMAPTPKMLMNAVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | KAT2B 2877/4885MAPT 2228/4885PKM 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.